Neoadjuvant PARPi for urothelial carcinoma: between lifeline and desperation

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Future oncology (London, England) England), 2021-09, Vol.17 (25), p.3281-3283
Hauptverfasser:	Tayeh, Georges Abi, Alkassis, Marwan, Semaan, Albert, Khalil, Nour, Nemr, Elie, Waked, Chady
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Transitional Cell - genetics Carcinoma, Transitional Cell - immunology Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - therapy cisplatin Cisplatin - pharmacology Cisplatin - therapeutic use Cystectomy Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Drug Resistance, Neoplasm - immunology Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use neoadjuvant Neoadjuvant Therapy - methods PARP inhibitors Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Progression-Free Survival targeted therapies Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - immunology Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - therapy urothelial carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!